The Kenneth Rainin Foundation supports high-risk, high-reward research to improve the lives of people suffering from Inflammatory Bowel Disease (IBD). At biomedical start-ups, seed funding is critical to advancing innovative but untested ideas for new therapies. By providing early support, the Foundation helps scientists prove concepts, de-risk their research and generate the critical data that pave the way for larger funders and biotech investors to take the next step.
Our early and ongoing investments in three companies help illustrate the opportunities and challenges in this sector. Azora Therapeutics and Thetis Pharmaceuticals are clinical-stage biopharmaceutical companies developing alternatives to immuno-suppressive therapies. G-Tech Medical has developed a non-invasive technology to monitor gut motility.
Our new blog series features conversations with leaders at these companies to highlight how early-stage investments accelerated their novel ideas and how our ongoing partnership has supported their evolving work.
Explore The Conversations:
- A Botanical Extract Shows Promising Results In Refractory Ulcerative Colitis with Julie Saiki, PhD, Co-Founder and Chief Operating Officer for Azora Therapeutics
- Novel IBD Therapy Targets Healing Not Just Inflammation with Gary Mathias, Co-Founder and CEO at Thetis Pharmaceuticals
- Tracking Gut Motility To Better Understand IBD with Steve Axelrod, PhD, President and CEO at G-Tech Medical
